MTND5P30

Across TCGA pan-cancer cohorts, MTND5P30 RNA is linked to patient survival in 10 of 34 cancer types, making it the most broadly survival-associated MTND5P30 data layer.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher MTND5P30 RNA is associated with worse disease-free survival. In most high-consensus cancer types, elevated MTND5P30 expression acts as an unfavorable survival marker.

LIHC, KIRP, and SKCM are the cancer types where MTND5P30 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	DFS	Tertile	All	0.333	0.576	<.001	102	view →
KIRP	OS	Tertile	III,IV	0.168	0.670	.001	63	view →
SKCM	DFS	Tertile	IV	0.016	0.454	<.001	45	view →
STAD	DFS	Tertile	All	0.509	0.737	.015	39	view →
BRCA	OS	Tertile	IV	0.233	0.755	.038	36	view →
COAD	OS	Tertile	IV	0.039	0.660	<.001	36	view →
UCEC	DFS	Tertile	All	0.463	0.656	.011	24	view →
UCS	OS	Tertile	IV	0.253	0.691	.022	18	view →
SARC	DFS	Tertile	All	0.095	0.632	.002	9	view →
KIRC	OS	Tertile	II,III,IV	0.567	0.813	.019	6	view →

Pink = unfavorable, green = favorable. Showing the 10 strongest of 10 lineages.

MTND5P30–LIHC (DFS)

Open the LIHC breakdown →